- Home
- » Tags
- » Glembatumumab vedotin
Top View
- Progress in the Management of Metastatic Breast Cancer in 2018: Is a Cure in the Horizon? by Gerardo Colón-Otero, MD
- (INN) for Biological and Biotechnological Substances
- Considerations for the Nonclinical Safety Evaluation of Antibody–Drug Conjugates
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
- Insights Into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
- October 2018 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
- Glembatumumab Vedotin AACR-NCI-EORTC-2013
- Targeting Oncogenic Vulnerabilities in Triple Negative Breast Cancer: Biological Bases and Ongoing Clinical Studies
- A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer
- Wo 2016/207089 Ai W I P O 29
- Understanding Cancer Immunotherapy
- Global Antibody-Drug Conjugate (ADC) Clinical Trial Review Global Antibody-Drug Conjugate (ADC)
- Precision Medicine in Breast Cancer
- Glembatumumab Vedotin for Patients with Metastatic, Gpnmb Overexpressing, Triple-Negative Breast Cancer (“METRIC”): a Randomized Multicenter Study ✉ Linda T
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
- A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma
- The Global Marine Pharmaceutical I Li Pipeline
- Current Treatment Landscape for Patients with Locally Recurrent Inoperable Or Metastatic Triple-Negative Breast Cancer: a Systematic Literature Review Claire H
- IMSN Open Letter on Antibody-Drug Conjugate 2151012
- Immunotherapy for Breast Cancer Treatment
- Glembatumumab Vedotin (CDX-011) in Patients with Metastatic, Gpnmb
- Oncology Drugs in the Pipeline
- Cancer Cell Targeting: Why Are So Few Antibody-Drug Conjugates Fda Approved?
- Patient Selection Strategies to Maximize Therapeutic Index Of
- Glembatumumab Vedotin 10-2016.Indd
- Download Download
- Glembatumumab Vedotin, an Anti-Gpnmb Antibody-Drug Conjugate (ADC), in Combination With
- CDX-011; CR011-Vcmm
- Antibody-Drug Conjugates in Breast Cancer: New Era in Cancer Treatment
- Inertly Labeled Monoclonal Antibodies for PET and Optical Imaging
- 1770.Full-Text.Pdf
- (INN) for Biological and Biotechnological Substances
- (19) United States Mar. 12, 2015
- Oncology Drugs in the Pipeline
- Thesis (PDF, 14.95MB)
- Are There Any Clinically Relevant Subgroups of Triple-Negative Breast Cancer in 2018? Jack J
- Current Status of Marine-Derived Compounds As Warheads in Anti-Tumor Drug Candidates
- Celldex Therapeutics Initiates Phase 1/2 Study of Varlilumab in Combination with Atezolizumab in Renal Cell Carcinoma
- Breast Cancer in Focus
- A Phase 2 Study of Glembatumumab Vedotin, an Antibody Drug Conjugate Targeting Gpnmb, in Advanced Melanoma
- Breast Cancer Treatment and Antibody Drug Conjugates: Beyond T-DM1
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
- Antibodies to Watch in 2018